A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease

Transl Neurodegener. 2023 Nov 16;12(1):54. doi: 10.1186/s40035-023-00387-5.

Abstract

Trial registration: ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic.

Clinicaltrials: gov/ct2/show/NCT05821153.

Publication types

  • Clinical Trial, Phase I
  • Letter

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Humans
  • Immunotherapy
  • Pilot Projects
  • Treatment Outcome

Associated data

  • ClinicalTrials.gov/NCT05821153